This site is intended for healthcare professionals

Cardiovascular and renal outcomes with dapagliflozin in people with chronic kidney disease: the DAPA-CKD study

Posted 13 Oct 2020

Dr Kevin Fernando

Dr Kevin Fernando summarises the practice-changing findings from this study, which included both patients with and patients without type 2 diabetes.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.